Our product range

Our development pipeline

Phase 1

Phase 2

Phase 3

Approval

Launch

IgG Next Generation (BT595) - Primary Immune Deficiency (PID)
IgG Next Generation (BT595) - Idiopathic Thrombocytopenic Purpura (ITP)
Fibrinogen (BT524) - Congenital fibrinogen deficiency
Fibrinogen (BT524) - Acquired fibrinogen deficiency
Trimodulin (BT588) - Severe community acquired pneumonia

Pipeline

Overview of all projects and their status from the therapy areas Haematology, Immunology and Intensive care medicine

Press releases

Biotest achieves significant milestone by completing ph...

26.05.2020,

26.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ... [More]

Biotest increases sales by 26%

08.05.2020,

08.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ... [More]

Annual General Meeting approves dividend distribution

08.05.2020,

08.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ... [More]

Biotest produces life-saving medicine derived from plas...

06.04.2020,

06.04.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ... [More]

Biotest is developing with Trimodulin a COVID-19 therap...

03.04.2020,

03.04.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ... [More]

Biotest exceeds EBIT forecast in the 2019 financial yea...

30.03.2020,

30.03.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ... [More]

Release according to Article 40, Section 1 of the WpHG ...

02.03.2020,

02.03.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ... ... [More]

Biotest exceeds already raised EBIT guidance

26.02.2020,

Announcement according to Article 17 European Market Abuse Regulation (MAR)Biotest exceeds already raised EBIT guidanceDreieich, 26 February 2020. According to preliminary and unaudited figures, the B ... [More]

Release according to Article 40, Section 1 of the WpHG ...

25.02.2020,

25.02.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ... ... [More]

Biotest's CMV-specific hyperimmunoglobulin Cytotect CP ...

15.01.2020,

15.01.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ... [More]

Biotest hosts first international symposium to increase...

17.12.2019,

17.12.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ... [More]

Biotest AG opens fourth plasma collection centre in Cze...

11.12.2019,

11.12.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ... [More]

Biotest AG increases Guidance

04.12.2019,

Announcement according to Article 17 European Market Abuse Regulation (MAR)Biotest AG increases GuidanceDreieich, 4 December 2019. Following the evaluation of the current business situation, the Manag ... [More]

Release according to Article 40, Section 1 of the WpHG ...

18.11.2019,

18.11.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ... ... [More]

Biotest increases sales by 1.8% to EUR 294.9 million

14.11.2019,

14.11.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ... [More]

Biotest shows excellent efficacy and tolerability of Ha...

29.10.2019,

Biotest shows excellent efficacy and tolerability of Haemoctin(R) SDH in long-term study of patients with haemophilia A - Clinical data of the worldwide longest surveillance study on198 patients repre ... [More]

Biotest Achieves Important Clinical Milestone for IgG N...

05.09.2019,

Biotest Achieves Important Clinical Milestone for IgG Next Generation- Phase III study in Primary Immune Thrombocytopenia (ITP) completed, data evaluation in progress, promising results - The study is ... [More]

Biotest increases adjusted EBIT by 12% to EUR 29.9 mill...

14.08.2019,

Biotest increases adjusted EBIT by 12% to EUR 29.9 million- Earnings after taxes reaches EUR 2.0 million- Expansion project Biotest Next Level proceeding according to plan- Long-term financing of the ... [More]

Annual general meeting approves payout of dividend

07.05.2019,

Biotest AG: Annual general meeting approves payout of dividend- Dividend payout of EUR 0.04 per preference shareDreieich/ Frankfurt a. M., 07 May 2019. At the annual general meeting (AGM) held on 07 M ... [More]

Biotest reaches revenues of EUR 77.5 million in the fir...

07.05.2019,

Biotest reaches revenues of EUR 77.5 million in the first quarter 2019 - Guidance confirmed- Earnings after taxes in the first quarter totalled to EUR -1.2 million Dreieich, 7 May 2019. In the first q ... [More]

Careers

Careers

Passionate to help us save lives?

Investor Relations

Investor Relations

The primary objective of our Investor Relations activities is an open and up-to-date dialogue with the financial community.